Gahart Martin T, Duhamel Louise M, Dievler Anne, Price Roseanne
Health Care Issues Team, U.S. General Accounting Office (GAO), Washington, DC, USA.
Health Aff (Millwood). 2003 Jan-Jun;Suppl Web Exclusives:W3-120-3. doi: 10.1377/hlthaff.w3.120.
Our analysis examined the effects of the Food and Drug Administration's (FDA's) 1997 draft guidance regarding advertisements for prescription drugs broadcast directly to consumers. We found that although direct-to-consumer (DTC) advertising spending by pharmaceutical companies has increased, more than 80 percent of their promotional spending is directed to physicians. DTC advertising appears to increase the use of prescription drugs among consumers. The FDA's oversight has not prevented companies from making misleading claims in subsequent advertisements, and a recent policy change has lengthened the FDA's review process, raising the possibility that some misleading campaigns could run their course before review.
我们的分析研究了美国食品药品监督管理局（FDA）1997年关于直接面向消费者的处方药广告的指导草案的影响。我们发现，尽管制药公司在面向消费者的直接广告（DTC）上的支出有所增加，但他们超过80%的促销支出是针对医生的。DTC广告似乎增加了消费者对处方药的使用。FDA的监管未能阻止公司在后续广告中做出误导性声明，而且最近的一项政策变化延长了FDA的审查过程，增加了一些误导性广告活动在审查之前就得以进行的可能性。
